ArticleShock (Augusta, Ga.)2026
Recombinant Klotho Protein Protects Tissues by Mitigating the Detrimental Effects of Sterile Inflammation After Hemorrhagic Shock.
Article in Shock (Augusta, Ga.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemorrhagic shock (HS) is a life-threatening condition characterized by systemic hypoperfusion, which induces inflammatory responses, oxidative stress, and apoptosis, often leading to multiple organ failure. Klotho, an antiaging protein with anti-inflammatory, antiapoptotic, and antioxidative properties, has demonstrated therapeutic potential in chronic diseases. However, its efficacy in acute conditions, such as HS, remains unexplored.
objectiveThis study investigated the protective effects of recombinant klotho protein (rKL) on the lungs and kidneys after HS and elucidated the underlying mechanisms.
methodsAdult male Wistar rats were subjected to controlled HS, followed by resuscitation. The animals were divided into four groups: sham, sham + rKL, HS, and HS + rKL. Histopathological analysis, terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick end labeling assay, reactive oxygen species (ROS) staining, enzyme-linked immunosorbent assay, real-time polymerase chain reaction, cytokine array, immunofluorescence staining for M1 and M2 macrophage markers, and high mobility group box-1 protein were performed to evaluate inflammation, apoptosis, and macrophage polarization.
resultsrKL administration markedly attenuated histological tissue damage in the lungs and kidneys, reduced lactate levels, and suppressed apoptosis and ROS accumulation. Furthermore, rKL inhibited the extracellular release of high mobility group box-1 protein and decreased the expression of proinflammatory cytokines. rKL also reduced macrophage infiltration and M1 polarization while increasing the M2/M1 ratio, indicating enhanced resolution of inflammation.
conclusionsrKL attenuates tissue injury after HS by reducing ROS, apoptosis, and inflammation, as well as modulating macrophage polarization. These findings suggest that rKL may serve as a promising adjunctive therapeutic strategy for improving HS outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.